The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc#039...
(Reuters) - The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc’s biosimilar to Roche AG’s blockbuster treatment for breast cancer, Herceptin.
The approval comes nearly a year after the agency declined to approve the drug, Trazimera, asking for additional technical information.
Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel
Monday, March 25, 2019